

Table 20.28

## Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014  
All Races, Both Sexes, by site

Histology <sup>a</sup>	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma <sup>b</sup> (8051-8131)	44,599	85.2%	2,931	94.4%	15,420	97.5%	1,239	21.7%	2,383	95.8%
Squamous cell carcinoma (8070-8078,8083-8084)	43,561	83.2%	2,814	90.6%	15,151	95.8%	1,186	20.8%	2,357	94.8%
Adenocarcinoma <sup>c</sup>	5,098	9.7%	122	3.9%	203	1.3%	3,561	62.4%	75	3.0%
Other specific carcinomas <sup>d</sup>	458	0.9%	-	-	38	0.2%	266	4.7%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,563	3.0%	-	-	82	0.5%	431	7.5%	-	-
Sarcoma and soft tissue <sup>e</sup>	169	0.3%	-	-	22	0.1%	36	0.6%	-	-
Other specific types <sup>f</sup>	284	0.5%	24	0.8%	-	-	119	2.1%	-	-
Unspecified (8000-8005)	203	0.4%	-	-	43	0.3%	58	1.0%	-	-
Total	52,375	100.0%	3,106	100.0%	15,821	100.0%	5,710	100.0%	2,487	100.0%

  

Histology <sup>a</sup>	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma <sup>b</sup> (8051-8131)	5,653	82.3%	1,804	64.6%	11,523	98.0%	2,698	97.6%	948	89.1%
Squamous cell carcinoma (8070-8078,8083-8084)	5,385	78.4%	1,662	59.5%	11,387	96.8%	2,683	97.1%	936	88.0%
Adenocarcinoma <sup>c</sup>	972	14.2%	72	2.6%	62	0.5%	-	-	19	1.8%
Other specific carcinomas <sup>d</sup>	30	0.4%	42	1.5%	40	0.3%	-	-	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	61	0.9%	808	29.0%	92	0.8%	24	0.9%	46	4.3%
Sarcoma and soft tissue <sup>e</sup>	35	0.5%	32	1.1%	-	-	-	-	-	-
Other specific types <sup>f</sup>	97	1.4%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	20	0.3%	18	0.6%	26	0.2%	-	-	27	2.5%
Total	6,869	100.0%	2,791	100.0%	11,763	100.0%	2,764	100.0%	1,064	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>c</sup> Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>d</sup> Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

<sup>e</sup> Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

<sup>f</sup> Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.